Genmab A/S (GMAB)
Health Care
Genmab A/S (GMAB) is listed on Nasdaq, where its shares have traded since October 5, 2010. SentiSense covers Genmab A/S in the Health Care sector. Jan van de Winkel is its chief executive officer. The company reports 3,119 employees, and its corporate website is www.genmab.com.
About Genmab A/S
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 289 institutions reported holding GMAB, with 102.1 million shares worth $2.8 billion in aggregate. The largest reported holders were Paradigm Biocapital Advisors, Orbis Allan Gray and Alliancebernstein. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on GMAB
- GMAB sentiment: whether news and social coverage of Genmab A/S leans bullish or bearish, and the stories driving it.
- GMAB ownership: all 289 reporting institutions, plus insider and congressional trades.
- GMAB financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Genmab A/S: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Genmab A/S do?
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer.
What sector is GMAB in?
SentiSense classifies Genmab A/S in the Health Care sector.
Where does GMAB stock trade?
Genmab A/S (GMAB) is listed on Nasdaq, where its shares have traded since October 5, 2010.
Who is the CEO of Genmab A/S?
Jan van de Winkel is the chief executive officer of Genmab A/S.